<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58606">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01783834</url>
  </required_header>
  <id_info>
    <org_study_id>2008-GIRBA-1739</org_study_id>
    <nct_id>NCT01783834</nct_id>
  </id_info>
  <brief_title>Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gachon University Gil Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for
      patients with previous treated non-small cell lung cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>5years</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Previous Treated Metastatic Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>pemetrexed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pemetrexed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gefitinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>gefitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <arm_group_label>gefitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>pemetrexed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cells pathologically diagnosed as histological or radical surgery or     radiation
             therapy is not possible stage IIIB and stage IV non-small-cell lung cancer patients

          -  second line

          -  ECOG 0ï½ž2

          -  Patients with normal liver function and renal function

        Exclusion Criteria:

          -  Patients with severe acute infection requiring antibiotic therapy

          -  Patients who have received treatment in other areas of cancer within 5 years

          -  During pregnancy and lactation patients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hee Kyung Ahn, professor</last_name>
    <phone>+82-32-460-2625</phone>
    <email>hkahn@gilhospital.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gachon university Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HeeKyung Ahn, professor</last_name>
      <phone>+82-32-460-2625</phone>
      <email>hkahn@gilhospital.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 19, 2013</lastchanged_date>
  <firstreceived_date>January 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gachon University Gil Medical Center</investigator_affiliation>
    <investigator_full_name>Eun Kyung Cho</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Pemetrexed</keyword>
  <keyword>Gefitinib</keyword>
  <keyword>iressa</keyword>
  <keyword>alimta</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
